Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Aeon Biopharma Sub Inc. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. The busiest examiner for the portfolio is LALONDE, ALEXANDRA ELIZABETH, who is handling 1 pending office action. With each of the 3 pending actions assigned to a different examiner and art unit, the company must navigate three distinct prosecution environments within the Biotechnology & Pharmaceuticals field.
This one-to-one ratio of actions to examiners and art units suggests that the company's current active matters are technically diverse. Practitioners should be prepared for three different sets of feedback, as there is no overlap to provide a consistent prosecution baseline. The 3 pending office actions require individual attention to the specific preferences of each examiner and the standards of each art unit. Success in the Biotechnology & Pharmaceuticals sector for Aeon Biopharma Sub Inc. will depend on effectively managing these three separate tracks. The lack of concentration among the 3 examiners means that no single individual's decision will disproportionately affect the entire pending portfolio, but it also means three separate sets of procedural hurdles must be overcome.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LALONDE, ALEXANDRA ELIZABETH | 1 | 71.2% | +32.8% |
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278937 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE | IANNUZO, NATALIE NMN | 31d overdue |
| 17911089 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS | JACKSON-TONGUE, LAKIA J | 34d |
| 18682352 | SINGLE-USE NEUROTOXIN FORMULATIONS AND PACKAGING | LALONDE, ALEXANDRA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278937 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE | IANNUZO, NATALIE NMN | 31d overdue |
| 17911089 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS | JACKSON-TONGUE, LAKIA J | 34d |
| 18682352 | SINGLE-USE NEUROTOXIN FORMULATIONS AND PACKAGING | LALONDE, ALEXANDRA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 1653 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682352 | SINGLE-USE NEUROTOXIN FORMULATIONS AND PACKAGING | LALONDE, ALEXANDRA ELIZABETH | 3783 | §102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18278937 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE | IANNUZO, NATALIE NMN | 1653 | §103§112DP | Final Rejection | 31d overdue | Pending | Aug 25, 2023 |
| 17911089 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS | JACKSON-TONGUE, LAKIA J | 1645 | §102§103 | Final Rejection | 34d | Pending | Sep 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAeon Biopharma Sub Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Alexandra Elizabeth Lalonde has the most, with 1 of Aeon Biopharma Sub Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
